Clinical Trial Search

Primary: Percentage of Participants With Human Immunodeficiency Virus -1 Ribonucleic Acid (HIV-1 RNA) <50 Copies/mL — 8.6; 26.2; 40.0; 56.3 percentage of participants

Primary: Time to Treatment Failure (PI Comparison) — 16; 16; 40; 24 weeks — p=<0.01

Primary: Difference in Proportion With Failure (Clinical or Virological) — 0; 3; 0; 0 Participants — p== 0.004

Primary: Confirmed Virologic Failure at or Prior to Week 48 — 95; 105; 34; 23 participants — p=0.133

Primary: Percent of Participants With Regimen Failure, Defined as a Confirmed Virologic Failure or Discontinuation of Randomized NRTI Component of Study Treatment — 26.0; 29.8…

Primary: Time From Randomization to Virologic Failure — 36; 24; 24; 24 Weeks

Primary: Cumulative Probability of First Virologic Failure by Week 96 — 13; 10; 15 cumulative probability per 100 persons

Primary: Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks — 0.64; 0.44; 0.88; 0.88 proportion of participants

Primary: Number of Participants With Sustained Virologic Response — 33 Participants

Primary: Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Load <50 Copies/Milliliter (mL) at 48 Weeks. — 77.92 Percentage of…

Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants

Primary: Percentage of Participants in Therapeutic Success — 40 percentage of participants

Primary: Change in Levels of CD8+ T-cell Activation (Defined as the Percentage HLA-DR+/CD38+) From Baseline to Weeks 24 and 48 on ART — -4.01 % of CD8+ T-cells — p=0.001

Primary: Flow-mediated Dilation of the Brachial Artery — 2.25; 3.36 percent dilation of the brachial artery — p=0.52

Primary: The Primary Outcome of This Study is the Proportion of Patients Having Detectable HIV-1 RNA Using the Single Copy Assay After 48 Weeks of Treatment and the Study…

Primary: Number of Participants With Virologic Suppression — 274; 256; 160 Participants

Primary: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) — 0 percentage of participants

Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants

Primary: Change in Viral Load Measured in log10 HIV-1 RNA Copies/ml — -3.16; -3.31; -3.26; -3.20 log10 HIV-1 RNA — p=0.26

Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12

Primary: Infant HIV Infection Status — 24; 11; 12 participants — p=.046

Primary: Number of Treatment-naïve Participants With Human Immunodeficiency Virus Ribonucleic Acid (HIV-RNA) Levels Less Than (<)50 Copies/Milliliter (c/mL) at 24 Weeks After 2DR…

Primary: Number of Participants With Mucosal Binding IgG Antibodies to HIV CN54gp140 Antigen — 0; 3; 1; 6 Participants

Primary: Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24 — 28 participants

Primary: Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT) — 8.2; 10.7; 12.9 micron/year — p=0.013

Primary: Virologic Response (Food Drug and Administration [FDA] Snapshot, Switch = Failure) — 87.0; 95.0 Percentage of Participants — p=0.2331

Primary: Virologic Status at Week 24 — 108; 5; 7 Participants

Primary: Change in Peak Oxygen Uptake. — 2.2; 2.8 ml/Kg/min — p=<0.05

Primary: Number of Participants With Treatment Emergent Adverse Events (AE) and All Serious AEs — 168; 110; 51; 10 participants

Primary: Insulin Resistance (HOMA Index) — 1.6; 1.8 units on a scale